Year: 2026
Type: article
Abstract: Therapeutic vaccines are emerging as a transformative class of biomedical interventions that extend the scope of vaccination from infection prevention to the treatment of malignancies, chronic infections, and autoimmune disorders.Traditional approaches employing live-attenuated or inactivated pathogens are limited in addressing rapidly evolving variants and diverse disease contexts, underscoring the need for next generation strategies.Recent advances in microbiome analytics, computational genomics, and single cell splicing atlases are accelerating the discovery of novel tumor-and disease-specific antigens with unprecedented precision.In parallel, nanoplatform engineering has produced delivery technologies such as lymph node targeting nanodiscs, polymeric co-delivery systems, and kinetically controlled adjuvants that enhance vaccine potency while minimizing off-target effects.Clinical and industrial efforts are actively translating these innovations through mRNA: lipid nanoparticle platforms, stem cell membrane derived biomimetic carriers, glioblastoma directed therapeutic vaccines, and radiotherapy nanomedicine combinations.Collectively, these interdisciplinary developments are reshaping the design and translation of therapeutic vaccines.While hurdles in manufacturing scalability, regulatory approval, and clinical validation remain, converging advances in molecular design, systems biology, and nanoengineering strongly support the integration of therapeutic vaccines as a cornerstone of future precision medicine.
Source: KOBRA Reports
Authors: Jaeeun Oh, Hyemin Cho, Sejin Son
Institution: Inha University
Language: English
Subfield: Immunology
Field: Immunology and Microbiology
Domain: Life Sciences
Open Access status: hybrid
Funder: Inha University
OpenAlex ID: W7124266861